Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Pancreatic Neoplasms 2Uterine Cervical Neoplasms 1Testicular Neoplasms 1Teratoma 1Sarcoma 1Rectal Neoplasms 1Ovarian Neoplasms 1Ovarian Germ Cell Cancer 1Ototoxicity 1Osteosarcoma 1Neuroblastoma 1Medulloblastoma 1Liver Neoplasms 1Hepatoblastoma 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Fatigue 1Colorectal Subepithelial Lesions 1Central Nervous System Neoplasms 1Brain Neoplasms 1Anus Neoplasms 1

Interventions

pembrolizumab 50Cyclophosphamide 25Carboplatin 25Gemcitabine 20Cisplatin 19fludarabine 18Nivolumab 17Paclitaxel 16Bevacizumab 15Specimen Handling 14Fluorouracil 11Magnetic Resonance Spectroscopy 10aldesleukin 9Oxaliplatin 9Irinotecan 9Docetaxel 9Biopsy 9olaparib 8Trastuzumab 8durvalumab 7atezolizumab 7Hyperthermic Intraperitoneal Chemotherapy 7Albumin-Bound Paclitaxel 7Taxes 6Leucovorin 6Ipilimumab 6Interleukin-2 6Cetuximab 6Capecitabine 6130-nm albumin-bound paclitaxel 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Restraint, Physical × Gastrointestinal × Clear all
NCT00716976 2023-11-09

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Children's Oncology Group

Phase 3 Completed
131 enrolled 18 charts 1 FDA
CNSGastrointestinalGenitourinaryGynecologicSarcoma

Ovarian Germ Cell Cancer, Ototoxicity, Brain Neoplasms, Liver Neoplasms, Medulloblastoma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Teratoma, Testicular Neoplasms, Central Nervous System Neoplasms, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡